BERGAMI, MARIA FIORELLA
 Distribuzione geografica
Continente #
NA - Nord America 166
AS - Asia 91
EU - Europa 73
SA - Sud America 17
AF - Africa 6
Totale 353
Nazione #
US - Stati Uniti d'America 164
IE - Irlanda 25
SG - Singapore 25
CN - Cina 19
HK - Hong Kong 17
VN - Vietnam 15
RU - Federazione Russa 14
BR - Brasile 11
DE - Germania 11
FI - Finlandia 7
FR - Francia 4
IN - India 4
IT - Italia 4
JP - Giappone 4
ZA - Sudafrica 4
GB - Regno Unito 2
IQ - Iraq 2
SE - Svezia 2
VE - Venezuela 2
BH - Bahrain 1
CA - Canada 1
CL - Cile 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DM - Dominica 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
IL - Israele 1
LB - Libano 1
MN - Mongolia 1
MZ - Mozambico 1
PE - Perù 1
PL - Polonia 1
TM - Turkmenistan 1
UA - Ucraina 1
Totale 353
Città #
Dallas 37
Chandler 21
Dublin 21
Singapore 18
Hong Kong 17
Ashburn 15
San Jose 15
Ho Chi Minh City 9
New York 8
Beijing 7
Munich 7
Los Angeles 6
Helsinki 5
Boardman 4
Johannesburg 4
Tokyo 4
Lauterbourg 3
Lawrence 3
Medford 3
Princeton 3
Baghdad 2
Columbus 2
Denver 2
Hanoi 2
Moscow 2
Poplar 2
Pune 2
Shanghai 2
Stockholm 2
São Paulo 2
The Dalles 2
Turku 2
Ashgabat 1
Barbacena 1
Bogotá 1
Boston 1
Brooklyn 1
Buffalo 1
Bắc Giang 1
Cairo 1
Cajamar 1
Chennai 1
Ciudad Guayana 1
Cuenca 1
Des Moines 1
Düsseldorf 1
Frankfurt am Main 1
Goianira 1
Guarenas 1
Guarulhos 1
Haifa 1
Hamad Town 1
Huế 1
Jesúpolis 1
La Pintana 1
Lima 1
Malgobek 1
Maputo 1
Marseille 1
Mumbai 1
North Bergen 1
Orem 1
Prague 1
Quirinópolis 1
Redondo Beach 1
Rio Verde 1
Rome 1
Roseau 1
Rovello Porro 1
San Diego 1
San Francisco 1
Santo André 1
Seattle 1
Tianjin 1
Torres 1
Ulan Bator 1
Việt Yên District 1
Warsaw 1
Totale 280
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 148
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 118
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 91
Totale 357
Categoria #
all - tutte 1.330
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.330


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 0 0 0 0 1 1 0 7 2 9
2022/202355 4 8 0 7 4 3 0 1 25 0 3 0
2023/202433 4 4 0 2 1 13 0 1 0 2 2 4
2024/202566 2 3 0 0 0 2 1 6 18 5 11 18
2025/2026183 9 11 44 23 26 12 29 10 13 6 0 0
Totale 357